Home » Genzyme Announces FDA Enforcement Action Regarding Allston Plant
Genzyme Announces FDA Enforcement Action Regarding Allston Plant
Genzyme Corporation announced on Mar. 24 that the FDA notified the company yesterday afternoon that, while the agency recognizes Genzyme’s efforts, it intends to take enforcement action to ensure that products manufactured at the plant are made in compliance with good manufacturing practice regulations. The FDA enforcement action will likely result in a consent decree, under which a third party would inspect and review the plant’s operation for an extended period and certify compliance with FDA regulations. Under a consent decree, Genzyme also would be required to make payments to the government and could incur other costs.
Based on its initial communication with the agency and the medical need for patients, Genzyme expects that shipments of Cerezyme (imiglucerase for injection) and Fabrazyme (agalsidase beta), which are manufactured in Allston, will continue uninterrupted during the period of the enforcement action. In addition, Genzyme expects that shipments of Myozyme (alglucosidase alfa) produced at the 160-L scale, which is filled and finished in Allston, will continue uninterrupted. Genzyme also fills and finishes Thyrogen (thyrotropin alfa for injection) at the Allston plant and intends to discuss with the agency the company’s view that there is also a patient need for uninterrupted supply of this product. The discussions with the FDA are expected to occur over the next several weeks.
Genzyme will work cooperatively with the FDA to restore the agency’s confidence in its ability to operate the Allston plant at the highest standards, building on the progress it has made over the past year to address the manufacturing deficiencies at the Allston plant. This progress includes:
Retaining a leading quality assurance advisory firm to help develop a comprehensive strategy and risk mitigation plan. More than 30 expert consultants from this firm are currently working at the Allston plant or at other Genzyme manufacturing facilities. Naming a new site head and reorganizing and strengthening the management team at the facility.
Hiring two highly regarded industry veterans to serve as President of Global Manufacturing and Corporate Operations and Senior Vice President of Global Product Quality.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
- All news »